2022 ASTRO-Sumitomo Pharma-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge

2022 ASTRO-Sumitomo-Pfizer New Combination Therapy Challenge

Purpose

To catalyze new collaborative research opportunities, and to facilitate radiation oncology leadership in scientific discovery with the Sumitomo-Pfizer Alliance in the space of multimodality combination therapy. Funding for the 2022 ASTRO-Sumitomo-Pfizer New Combination Therapy Challenge was up to $2,500,000, across three projects.

Grantor

Sumitomo Sciences-Pfizer Alliance

Awardees

• Xinglei Shen, MD
  • Institution: University of Kansas Medical Center
  • Proposal: Quantifying optimal relugolix duration with radiation in high-risk cancer
• Shang-Jui Wang, MD, PhD
  • Institution: The Ohio State University
  • Proposal: A comparison of Orgovyx (relugolix) vs Eligard (leuprolide) on cardiovascular function and biomarkers during standard of care combined ADT (androgen deprivation therapy)-radiation for prostate cancer
• James Yu, MD, FASTRO
  • Institution: Yale School of Medicine
  • Proposal: Phase III SUGAR study: SBRT and Ultrashort GnRH Antagonist-Relugolix for clinicogenomic unfavorable intermediate risk prostate cancer

Award Information

• Challenge Statement/Research Areas of Interest
  • How can prostate cancer treatment be improved with the gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix in patients receiving radiotherapy?
    • Encouraged topics:
      • Use of relugolix with definitive radiotherapy (concomitant/adjuvant/neoadjuvant) in prostate cancer patients with high/very high risk, unfavorable intermediate risk and regional disease
      • Use of relugolix with radiotherapy as salvage therapy post treatment with curative intent
      • Concomitant treatment with other oral oncolytics (e.g., ARIs)
      • Synchronous oligometastatic/metastatic and oligoprogressive disease
    • Evaluation may include:
      • Clinical outcomes (i.e., rPFS, MFS, local control, etc.)
      • Testosterone kinetics
      • Patient-Reported Outcomes (PROs)
      • Safety/Adverse Events (AEs)
      • Compliance/adherence
      • Translational research such as exploratory biomarkers and mechanistic studies may be considered as part of a clinical trial
    • Out-of-scope topics:
      • Recurrent oligometastatic disease
      • Retrospective studies
      • All other tumor sites  
      • Ex-U.S. studies
• Geographic Scope: United States
• Eligible Organizations:
  • Higher Education Institutions
  • Nonprofits Other Than Institutions of Higher Education
  • Community Cancer Centers
• Due: 11:59 p.m. Eastern time on July 18, 2022 
• Resources: 
  • Challenge Program Announcement (PA).
  • Frequently Asked Questions (FAQ)

For additional information or to indicate interest in future Challenge partnerships, contact the Department of Scientific Affairs.